EUVIMEDEUVIMED entdecken
Crossref

HPV vaccination is highly effective and cost‐effective for cervical cancer prevention in women living with HIV in China: A cost‐effectiveness analysis

Hanting Liu, Maosheng Zou, Mingwang Shen, Adeeba Kamarulzaman, Simiao Chen, Jinghua Li, Rui Li, Huan Liu, Zhuoru Zou, Lei Zhang iD

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Hanting Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Statistics, School of Public Health, Sun Yat-Sen University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, HIV Infections, Papillomavirus Vaccines, Papillomavirus Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The presence of human immunodeficiency virus (HIV) infection increases the risk of acquiring human papillomavirus (HPV) infection and developing HPV‐related adversities. We aimed to estimate the cost‐effectiveness of HPV vaccination for women living with HIV in a Chinese setting. A decision‐analysis Markov model was developed to estimate the cost‐effectiveness of 36 HPV vaccination strategies for women living with HIV aged 18–45 years, from the healthcare system perspective. With the status quo, not vaccinating women living with HIV would lead to 51.99% (51,985/100,000) HIV‐related deaths; 35.10% (35,098/100,000) would develop genital warts, 0.36% (355/100,000) develop cervical cancer, and among which 63.66% (226/355) die from cervical cancer over their lifetime (1,601,457 person‐years). With a willingness to pay (WTP) threshold of three times gross domestic product (GDP), Gardasil 4 vaccination for all women living with HIV aged 18–45 years was the most cost‐effective strategy (ICER = US $32,766/QALY gained). This strategy would reduce genital warts by 35.52% (12,467/35,098), cervical cancers by 12.96% (46/355), and cervical cancer deaths by 12.39% (28/226) over the lifetime of the cohort. If the future domestic Cecolin 9 vaccine is priced at 60% of Gardasil 9, vaccinating all women living with HIV aged 18–45 years with Cecolin 9 would be the most cost‐effective strategy (ICER = US $30,493/QALY gained). Improving adherence to antiretroviral therapy for HIV may substantially improve the cost‐effectiveness of both Gardasil 4 and Cecolin 9 vaccination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsHIV InfectionsPapillomavirus VaccinesPapillomavirus InfectionsHumansFemaleAdultCost-Benefit AnalysisChinaMiddle AgedAdolescentYoung AdultMarkov ChainsQuality-Adjusted Life YearsVaccinationCost-Effectiveness Analysis

Stichwörter der Autor:innen

cervical cancercost‐effectiveness analysishuman immunodeficiency virushuman papillomavirusvaccine

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • Department of Medical Statistics, School of Public Health, Sun Yat-Sen University, Guangzhou, Guangdong, China.
  • Yangzhou Centre for Disease Control and Prevention, Jiangsu, China.
  • China-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China.
  • Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an, Shaanxi, China.
  • Monash University Malaysia, Kuala Lumpur, Malaysia.
  • International AIDS Society, Geneva, Switzerland.

ORCID-Profile: Lei Zhang

Zitieren

APA

Liu, H., Zou, M., Shen, M., Kamarulzaman, A., Chen, S., Li, J., Li, R., Liu, H., Zou, Z., & Zhang, L. (2025). HPV vaccination is highly effective and cost‐effective for cervical cancer prevention in women living with HIV in China: A cost‐effectiveness analysis. International Journal of Cancer. https://doi.org/10.1002/ijc.35242

Vancouver

Liu H, Zou M, Shen M, Kamarulzaman A, Chen S, Li J, et al. HPV vaccination is highly effective and cost‐effective for cervical cancer prevention in women living with HIV in China: A cost‐effectiveness analysis. International Journal of Cancer. 2025. doi:10.1002/ijc.35242

BibTeX
@article{Liu2025,
  author = {Liu, Hanting and Zou, Maosheng and Shen, Mingwang and Kamarulzaman, Adeeba and Chen, Simiao and Li, Jinghua and Li, Rui and Liu, Huan and Zou, Zhuoru and Zhang, Lei},
  title = {HPV vaccination is highly effective and cost‐effective for cervical cancer prevention in women living with HIV in China: A cost‐effectiveness analysis},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35242}
}
Kostenlos starten →